Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Psychosis and Antipsychotic Drugs: Overview

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dog- to- dog bite wound management - Comparison of the antiseptic efficacy of polyhexanide and hypochlorous acid with regard to reducing the use of antibiotics: A randomized clinical trial.

Veterinary journal (London, England : 1997)·2025

Same author

A stratified treatment algorithm in psychiatry: a program on stratified pharmacogenomics in severe mental illness (Psych-STRATA): concept, objectives and methodologies of a multidisciplinary project funded by Horizon Europe.

European archives of psychiatry and clinical neuroscience·2024

Same author

Effect of casozepine administration on stress in dogs during a veterinary examination - A randomized placebo-controlled trial.

Veterinary journal (London, England : 1997)·2024

Same author

Saliva Malondialdehyde Concentration of Dogs With and Without Periodontal Disease.

Journal of veterinary dentistry·2024

Same author

Effect of intra-articular platelet-rich plasma or hyaluronic acid on limb function recovery in dogs with TPLO for cranial cruciate ligament rupture: a randomised controlled trial.

The Journal of small animal practice·2024

Same author

Autologous point-of-care stromal vascular fraction transplantation in dogs with advanced osteoarthritis of the knee and hip joints.

Australian veterinary journal·2023

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

[Polypharmacy in schizophrenia].

M Zink¹, S Englisch, A Meyer-Lindenberg

¹Abteilung fürf Psychiatrie and Psychotherapie, Zentralinstitut für seelische Gesundheit, 68072, Mannheim, Deutschland. mathias.zink@zi-mannheim.de

|December 18, 2010

Summary

This summary is machine-generated.

Combination therapy for schizophrenia is common, especially for treatment-resistant cases. Evidence supports antidepressants for negative symptoms, but data for other combinations and cognitive symptoms remain limited, necessitating further research.

More Related Videos

Development of a Virtual Reality Assessment of Everyday Living Skills

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Related Experiment Videos

Last Updated: Jun 5, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Development of a Virtual Reality Assessment of Everyday Living Skills

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Area of Science:

Psychiatry and Pharmacology
Neuroscience

Context:

Schizophrenia treatment often involves polypharmacy despite guidelines recommending monotherapy with second-generation antipsychotics (SGA).
Combined psychotropic agent use is prevalent, particularly in treatment-refractory schizophrenia.
This review examines evidence for combined antipsychotic strategies and augmentation with other agents.

Purpose:

To review the evidence for combined antipsychotic treatment strategies in schizophrenia.
To evaluate augmentation of antipsychotics with mood stabilizers, antidepressants, and experimental substances.
To identify effective strategies for treatment-resistant schizophrenia symptoms.

Summary:

Antidepressant augmentation shows some efficacy for negative symptoms and depression in schizophrenia.
Lithium and mood stabilizers have limited evidence, potentially benefiting specific subgroups.
Cognitive remediation is promising for cognitive deficits; anticholinergics and benzodiazepines address acute side effects.
Clozapine monotherapy is recommended for treatment-resistant positive/negative symptoms; adding a second SGA is rarely indicated.

Impact:

Highlights the need for more rigorous randomized controlled trials (RCTs) and head-to-head studies.
Informs clinical practice regarding the limited evidence base for many combination therapies.
Suggests cognitive remediation as a key strategy for cognitive symptoms in schizophrenia.